Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Von Potter"'
Autor:
Antonio Omuro, Alba A Brandes, Antoine F Carpentier, Ahmed Idbaih, David A Reardon, Timothy Cloughesy, Ashley Sumrall, Joachim Baehring, Martin van den Bent, Oliver Bähr, Giuseppe Lombardi, Paul Mulholland, Ghazaleh Tabatabai, Ulrik Lassen, Juan Manuel Sepulveda, Mustafa Khasraw, Elodie Vauleon, Yoshihiro Muragaki, Anna Maria Di Giacomo, Nicholas Butowski, Patrick Roth, Xiaozhong Qian, Alex Z Fu, Yanfang Liu, Von Potter, Alexandros-Georgios Chalamandaris, Kay Tatsuoka, Michael Lim, Michael Weller
Publikováno v:
Neuro-Oncology, 25(1), 123-134. Oxford University Press
Background Addition of temozolomide (TMZ) to radiotherapy (RT) improves overall survival (OS) in patients with glioblastoma (GBM), but previous studies suggest that patients with tumors harboring an unmethylated MGMT promoter derive minimal benefit.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b68a372718b84388b72b49366cf2a9da
https://doi.org/10.1093/neuonc/noac099
https://doi.org/10.1093/neuonc/noac099
Autor:
Antonio Omuro, David A Reardon, John H Sampson, Joachim Baehring, Solmaz Sahebjam, Timothy F Cloughesy, Alexandros-Georgios Chalamandaris, Von Potter, Nicholas Butowski, Michael Lim
Publikováno v:
Neuro-oncology advances. 4(1)
BackgroundThe phase 1 cohorts (1c+1d) of CheckMate 143 (NCT02017717) evaluated the safety/tolerability and efficacy of nivolumab plus radiotherapy (RT) ± temozolomide (TMZ) in newly diagnosed glioblastoma.MethodsIn total, 136 patients were enrolled.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a15dffee15cda8ca995c353b0e667ce7
https://pubmed.ncbi.nlm.nih.gov/35402913
https://pubmed.ncbi.nlm.nih.gov/35402913
Autor:
Andrew J. Armstrong, Michael S. Gordon, Melissa A. Reimers, Arif Hussain, Vaibhav G. Patel, Elaine T. Lam, Alex Sedkov, Von Potter, Neal Shore
Publikováno v:
Molecular Cancer Therapeutics. 20:P202-P202
Background: Prostate cancer is the 2nd leading cause of cancer-related deaths among men in the US. CREB binding protein (CBP) and paralog p300 are co-activators of androgen receptor (AR) relevant to metastatic castration-resistant prostate cancer (mC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f6ff1be16862eb536eb2486f331e9eba
https://doi.org/10.1158/1535-7163.targ-21-p202
https://doi.org/10.1158/1535-7163.targ-21-p202
Autor:
Theodosia A. Kalfa, Thomas D. Coates, R. Clark Brown, Janet L. Kwiatkowski, Julie Brevard, Von Potter, Sujit Sheth, Ashutosh Lal, Ken Wood
Publikováno v:
Blood. 138:4162-4162
Background Sickle cell disease (SCD) and thalassemia are inherited hemoglobinopathies characterized by lifelong anemia. In SCD, a single mutation in the β-globin gene results in sickle hemoglobin (HbS) that polymerizes upon deoxygenation, causing re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::08fcda607c05948aa82c079f3616f9e9
https://doi.org/10.1182/blood-2021-145752
https://doi.org/10.1182/blood-2021-145752
Autor:
Sabine Coppieters, David Z. Chang, Carolina Soares Viana de Oliveira, Timothy S. Larson, Matthias Herpers, Kanwal Pratap Singh Raghav, Johanna C. Bendell, David Cosgrove, Neelesh Sharma, Ying A. Wang, Joseph A. Fiorillo, Marwan Fakih, Allen Lee Cohn, Timothy K. Huyck, Andrew Scott Paulson, David D'Adamo, Lawrence Garbo, Shruthi Ravimohan, Von Potter
Publikováno v:
Journal of Clinical Oncology. 39:3560-3560
3560 Background: The role of immunotherapy in the treatment of pMMR/MSS metastatic CRC is not established. A Japanese phase 1b trial in this setting showed the combination of regorafenib (multikinase inhibitor with immunomodulatory activity) plus niv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ffd68c75c2a495b3b6aed4bd45ab0165
https://doi.org/10.1200/jco.2021.39.15_suppl.3560
https://doi.org/10.1200/jco.2021.39.15_suppl.3560
Autor:
Satyendra Suryawanshi, Amit Roy, Michael Lim, Prashni Paliwal, Ricardo Zwirtes, Matthew Hruska, J. Shen, Von Potter, Akintunde Bello
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d12162be6a6514f1c656f3236e3bc246
https://europepmc.org/articles/PMC5692350/
https://europepmc.org/articles/PMC5692350/
Autor:
Von Potter, Patrick Roth, Juan Sepulveda, Ricardo Zwirtes, Paul Mulholland, Manmeet Ahluwalia, Antonio Omuro, Paul de Souza, Oliver Bähr, Michael Lim, Antje Wick, Michael Weller, Alba A. Brandes, David A. Reardon, John Sampson, Surasak Phuphanich, Corina Taitt, Joachim M. Baehring, Kay Tatsuoka, Solmaz Sahebjam
Publikováno v:
Neuro Oncol
BACKGROUND Current therapies for recurrent glioblastoma provide limited survival benefit. In the open-label, phase 3 CheckMate 143 study (NCT02017717), although the primary endpoint was not met, the median overall survival (mOS) was comparable betwee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::392d783ffa204b5fecab2c7a18a3e9be
https://doi.org/10.1093/neuonc/noz175.045
https://doi.org/10.1093/neuonc/noz175.045
Autor:
Gordana Vlahovic, N. Butowski, John Sampson, Solmaz Sahebjam, Michael Carleton, Alba A. Brandes, Michael Lim, T. Cloughesy, Prashni Paliwal, David A. Reardon, Antonio Omuro, Joachim M. Baehring, Ricardo Zwirtes, Von Potter
Publikováno v:
Annals of Oncology. 28:v109
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c9759f047abb658f0b7ba29707f30f0f
https://doi.org/10.1093/annonc/mdx366
https://doi.org/10.1093/annonc/mdx366
Publikováno v:
Cancer chemotherapy and pharmacology. 63(6)
Monoclonal antibodies (MAbs) targeting epidermal growth factor receptor (EGFR) are effective in treatment of metastatic colorectal cancer (mCRC). Cetuximab, a chimeric MAb targets EGFR. Even with premedication, cetuximab can cause a hypersensitivity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d304d94891eb0dc8f45fe7c1139b373
https://pubmed.ncbi.nlm.nih.gov/18781300
https://pubmed.ncbi.nlm.nih.gov/18781300
A Phase 1 Trial of Vorinostat and Pegylated Liposomal Doxorubicin In Relapsed or Refractory Lymphoma
Autor:
Stuart Seropian, Dennis L. Cooper, Francine M. Foss, Von Potter, Noelle Sowers, Frederick Lansigan
Publikováno v:
Blood. 116:2816-2816
Abstract 2816 Background: Vorinostat is a histone deacetylase inhibitor with activity in lymphoma and leukemia. Vorinostat has been reported to act synergistically with topoisomeraseII inhibitors such as anthracyclines (Ac) by facilitating an open ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f0d11617ef3570b51a41b6f9ffc67c0f
https://doi.org/10.1182/blood.v116.21.2816.2816
https://doi.org/10.1182/blood.v116.21.2816.2816